62 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Bayer-backed Boundless Bio sees stock fall 8% after $100M IPO https://seekingalpha.com/news/4085101-bayer-backed-boundless-bio-stock-falls-after-100m-ipo?source=feed_sector_healthcare Mar 28, 2024 - Bayer-backed Boundless Bio (BOLD) saw its shares drop 8% following a $100M initial public offering on Thursday. Read more here.
Mustang Bio stock climbs 9% amid drug development update https://seekingalpha.com/news/4085033-mustang-bio-stock-climbs-amid-drug-development-update?source=feed_sector_healthcare Mar 28, 2024 - Mustang Bio (MBIO) stock rose 9% Thursday after the company said it was planning to expand testing of its oncology drug candidate MB-106 into autoimmune diseases. Read more here.
Kronos Bio (KRON) Upgraded to Buy: What Does It Mean for the Stock? https://www.zacks.com/stock/news/2246863/kronos-bio-kron-upgraded-to-buy-what-does-it-mean-for-the-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246863 Mar 27, 2024 - Kronos Bio (KRON) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Instil Bio (TIL) a New Buy Stock https://www.zacks.com/stock/news/2246872/what-makes-instil-bio-til-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2246872 Mar 27, 2024 - Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report? https://www.zacks.com/stock/news/2246798/why-is-theravance-bio-tbph-down-9-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2246798 Mar 27, 2024 - Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline https://www.zacks.com/stock/news/2246721/earnings-preview-bluebird-bio-blue-q4-earnings-expected-to-decline?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2246721 Mar 27, 2024 - Bluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
bluebird bio falls as accounting errors force restatements https://seekingalpha.com/news/4083728-bluebird-bio-stock-falls-accounting-errors?source=feed_sector_healthcare Mar 26, 2024 - bluebird bio (BLUE) faces a significant stock drop after revealing accounting errors that force it to restate financials for 2022 and 2023. Read more here.
OPKO Health (OPK) And Entera Bio Announce Data for GLP-2 https://www.zacks.com/stock/news/2245547/opko-health-opk-and-entera-bio-announce-data-for-glp-2?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245547 Mar 25, 2024 - OPKO Health (OPK) and Entera Bio announce robust pharmacokinetic results for the proprietary GLP-2 agonist developed by OPK Heath.
bluebird bio Is Priced Below IP Value https://seekingalpha.com/article/4680031-bluebird-bio-is-priced-below-ip-value?source=feed_all_articles Mar 22, 2024 - bluebird bio's stock plummeted by 64% on safety concerns and high pricing for sickle cell treatment. Read why its potential sale value remains higher than its market cap.
Adicet Bio (ACET) Loses -16.39% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner https://www.zacks.com/stock/news/2244747/adicet-bio-acet-loses-16-39-in-4-weeks-here-s-why-a-trend-reversal-may-be-around-the-corner?cid=CS-ZC-FT-tale_of_the_tape|rsi-2244747 Mar 22, 2024 - The heavy selling pressure might have exhausted for Adicet Bio (ACET) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Pages: 1234567

Page 1>